-

USAntibiotics Expands Leadership Team with Appointment of Steven Lutz to Vice President of Strategic Accounts

BRISTOL, Tenn.--(BUSINESS WIRE)--USAntibiotics, the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Steven Lutz to vice president of strategic accounts. In this role, Lutz oversees the organization’s commercial strategy to drive continued growth and market share in alignment with the company’s business objectives.

An accomplished sales and marketing executive, Lutz has more than three decades of experience leading multi-faceted business development strategies in the pharmaceutical and biotechnology sectors.

At USAntibiotics, Lutz leads the overarching sales strategy with a focus on initiatives to optimize commercial efficiency, strengthen customer relationships and oversee third-party logistics.

“Steven’s proven success in driving strategic growth in the pharmaceutical market makes him a great addition to our team,” said Patrick Cashman, president, USAntibiotics. “His leadership will be instrumental as we further expand our market presence and advance our mission of producing life-saving antibiotics for the benefit of all Americans. We are delighted to welcome Steven to USAntibiotics and our executive leadership team.”

Before joining USAntibiotics, Lutz was on the leadership team at Neos Therapeutics. Prior to that, he co-founded Cornerstone Therapeutics, now Chiesi USA.

About USAntibiotics

USAntibiotics is the only U.S. manufacturer of Amoxicillin and Amoxicillin Clavulanate, commonly known as Amoxil® and Augmentin®. Based in Bristol, Tennessee, it operates a world-class, 394,000 square foot antibiotics production facility with the sole focus of making quality, life-saving antibiotics widely available for the benefit of all Americans. USAntibiotics is part of the Jackson Healthcare® family of companies. For more information, visit www.us-antibiotics.com.

Contacts

media@us-antibiotics.com

Industry:

USAntibiotics

Release Versions
English

Contacts

media@us-antibiotics.com

More News From USAntibiotics

FDA Approves USAntibiotics' Augmentin XR in Historic First for Expedited Review Program

BRISTOL, Tenn.--(BUSINESS WIRE)--USAntibiotics, the country's only domestic manufacturer of amoxicillin (Amoxil®) and amoxicillin clavulanate (Augmentin®), announced today that the U.S. Food and Drug Administration (FDA) has approved Augmentin XR (amoxicillin-clavulanate potassium) under the Commissioner's National Priority Voucher (CNPV) pilot program. The FDA’s re-approval marks the first drug approved through the CNPV expedited pathway and returns a critical extended-release antibiotic formu...

USAntibiotics Awarded FDA National Priority Voucher for Domestic Manufacturing of Critical Antibiotic

BRISTOL, Tenn.--(BUSINESS WIRE)--USAntibiotics, the country’s only domestic manufacturer of amoxicillin (Amoxil®) and amoxicillin clavulanate (Augmentin®), announced today that the U.S. Food and Drug Administration (FDA) selected its Augmentin XR product for the agency's inaugural Commissioner's National Priority Voucher (CNPV) Program. The new voucher promises a review decision within one to two months following submission of a complete application, collapsing the typical 10 to 12-month FDA ti...

USAntibiotics Working with Walmart and McKesson to Support U.S. Manufacturing of Amoxicillin

BRISTOL, Tenn.--(BUSINESS WIRE)--USAntibiotics, the nation’s lone remaining manufacturer of amoxicillin and amoxicillin clavulanate, today announced a new collaboration with Walmart and McKesson through their joint venture partner ClarusONE Sourcing Services to provide domestically manufactured antibiotics made by USAntibiotics in the United States for millions of patients nationwide. The collaboration will see USAntibiotics supply millions of life-saving doses of amoxicillin directly to Walmar...
Back to Newsroom